Anvisa recently approved the Covaxin clinical trial in Brazil, which will study the application of two doses, with 28 days of interval, involving 4,500 volunteers
The supplies of Covaxin will be prioritised for public market through direct procurement by Brazil government while the supplies to private market would be based upon receipt of market authorisation from the country's regulator
The Brazilian Association of Vaccine Clinics (ABCVAC) confirmed on its website it had signed a memorandum of understanding with the Indian firm to purchase its Covaxin vaccine
